Lower extremity lymphedema after pelvic nodal dissection for urologic cancers is associated with metastatic recurrence

Authors

  • Kaylyn Pogson University of North Carolina, Chapel Hill
  • Gianpaolo P. Carpinito University of North Carolina, Chapel Hill
  • Fernando Mijares-Diaz University of North Carolina, Chapel Hill
  • Sabrina A. Mangat University of North Carolina, Chapel Hill
  • Kamran Khan University of North Carolina, Chapel Hill
  • Marc A. Bjurlin University of North Carolina, Chapel Hill
  • Adeyemi Ogunleye University of North Carolina, Chapel Hill

DOI:

https://doi.org/10.5489/cuaj.9193

Keywords:

lymphedema, lower extremity lymphedema, pelvic lymph node dissection, urologic malignancy

Abstract

INTRODUCTION: We aimed to evaluate the incidence and risk factors for lymphedema secondary to pelvic lymph node dissection (PLND) in urologic surgery. Secondary lymphedema is the most common type of lymphedema in the U.S. and the role of PLND in lower extremity lymphedema etiology is less well-defined.

METHODS: We performed a retrospective review of all PLNDs performed for urologic malignancies at a single academic institution between April 2014 and April 2017. Patient demographics, comorbidities, cancer staging, and other treatment information were collected. Incidence of lower extremity lymphedema and associated risk factors were explored. Univariate analysis and multivariate logistic regression were performed.

RESULTS: A total of 235 patients were included in our study. Mean (standard deviation) age was 68.8 (8.9) years, and the mean followup duration was 2.4 (1.7) years. Lymphedema occurred in 22 (9.4%) patients, and the mean time to lymphedema diagnosis was 7.4 (8.0) months. Age, body mass index, smoking, diabetes, pre- or postoperative radiation, number of resected lymph nodes, and number of positive lymph nodes were not significantly associated with postoperative lower extremity lymphedema; however, metastatic recurrence was significantly associated with the development of postoperative lymphedema. (odds ratio 2.83, 95% confidence interval 1.1-7.32, p=0.03).

CONCLUSIONS: While the incidence of lower extremity lymphedema after PLND is low in urologic cancer patients, this complication is associated with metastatic recurrence. These results may allow for improved preoperative counseling on the risk of lower extremity lymphedema and inform cancer surveillance in patients with this complication. More research is needed to elucidate this association.

Downloads

Download data is not yet available.

Downloads

Published

2025-07-28

How to Cite

Pogson, K., Carpinito, G. P., Mijares-Diaz, F., Mangat, S. A., Khan, K., Bjurlin, M. A., & Ogunleye, A. (2025). Lower extremity lymphedema after pelvic nodal dissection for urologic cancers is associated with metastatic recurrence. Canadian Urological Association Journal, 19(11), E386–91. https://doi.org/10.5489/cuaj.9193

Issue

Vol. 19 No. 11 (2025): CUAJ November

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.